Signatera EU IVDR Certification: A Step Forward, But Operating Leverage Remains Elusive

What happened

Natera's Signatera MRD test for solid tumors earned EU IVDR certification, marking a key regulatory milestone that supports broader commercialization across Europe. This certification strengthens Natera's international expansion narrative, potentially unlocking incremental volumes in a market where the company previously had limited presence. However, the company's Q1 2026 results revealed a persistent tension: revenue grew 39% year-over-year to $696.6M, but operating loss widened to $(93.5)M as R&D and SG&A expenses outpaced revenue growth. The certification does not address the core investment debate around when scale will translate into narrowing losses, especially given accelerating competition from Labcorp and Foundation Medicine. Until Natera demonstrates that revenue growth can sustainably outpace expense growth, the stock's current valuation at ~$219 (above the deep value report's attractive entry of $190) leaves limited margin of safety.

Implication

Investors should view the IVDR certification as a positive but incremental catalyst within Natera's broader narrative, as it primarily opens a new geographic revenue stream rather than addressing the company's fundamental profitability challenge. The key near-term proof points remain Q2 and Q3 2026 results showing whether operating losses narrow, oncology unit growth remains robust, and gross margin holds within the 64%-66% guide. With the stock trading at $219, near the deep value report's trim-above level of $250, and given the widening operating loss from Q1, risk/reward is not compelling. The more attractive entry point remains closer to $190, where the bear case of slower growth and persistent losses is better discounted.

Thesis delta

The EU IVDR certification introduces a credible international growth vector that was previously more speculative, incrementally supporting the bull case. However, it does not alter the central thesis tension: Natera must demonstrate operating leverage from its domestic volume scale to justify current multiples, and this certification does not change the near-term financial trajectory. The watch-and-wait rating remains appropriate, as the fundamental question of expense discipline remains unresolved.